Information about the abatacept (Orencia®) Shortage

The shortages of abatacept (Orencia®) subcutaneous products in Australia will be resolved from 1 July 2022.

From this date, what this means is:

  • The Serious Scarcity Substitution Instrument (SSSI) and the TGA shortage notification for the SC preparations of Orencia will no longer be in place
  • The Orencia Stock Hypercare Plan (OSHP) will be ceased and normal prescribing and ordering processes for all Orencia presentations will resume
  • Patients may switch back to, and new patients may be initiated on, any of the Orencia presentations (IV or SC) as deemed appropriate by their treating physician

Arthritis Australia has worked closely with the TGA, Bristol Myers Squibb (BMS), and the Australian Rheumatology Association (ARA) to manage the shortages. BMS have advised that they wish to thank consumers, their treating physicians, and pharmacists for their patience during this extremely challenging situation.

Stock of the intravenous (IV) abatacept Orencia presentation has also recently improved and new patients can be started on this medicine.

Consumers should contact their rheumatologists for further advice.

 

Consumer webinar

A Consumer Webinar was held and recorded on 2 March 2022 to share more about this issue and have questions answered by representatives from the ARA, TGA, BMS Australia and Arthritis Australia.

Panellists:

Catherine Hill, Australian Rheumatology Association

Elspeth Kay, Therapeutic Goods Administration

Neil MacGregor, Bristol-Myers Squibb Australia

Louise Hardy, Arthritis Australia

Watch the recording of this webinar

 

Further information and support

 

Updated 20 June 2022